Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: A multi-site, placebo-controlled pilot trial

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 6, 2007, Pages 791-801

  Arnold, L Eugene ^a   Amato, Antonino ^b   Bozzolo, Hernan ^c   Hollway, Jill ^a   Cook, Amy ^a   Ramadan, Yaser ^a   Crowl, Lindsay ^a   Zhang, Dan ^b   Thompson, Susan ^a   Testa, Giussepe ^b   Kliewer, Vernon ^d   Wigal, Timothy ^e   McBurnett, Keith ^f   Manos, Michael ^g  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Sigma Tau Pharmaceuticals Inc   (United States)

^c US Government Accountability Office   (United States)

^d Prairie View Mental Health Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVACECARNINE; PLACEBO;

ANALYSIS OF VARIANCE; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; CHILD; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INFECTION; INFESTATION; INJURY; INTOXICATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NOSE CONGESTION; NUTRITIONAL DISORDER; PHARYNGITIS; PHYSICAL EXAMINATION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; SUBCUTANEOUS TISSUE DISEASE; TREATMENT DURATION; TREATMENT OUTCOME;

ACETYLCARNITINE; ANALYSIS OF VARIANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; ELECTROCARDIOGRAPHY; FACULTY; FEMALE; HUMANS; MALE; NOOTROPIC AGENTS; PARENTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME;

EID: 38549087388     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2007.018     Document Type: Article

References (35)

1. Arduini A, Mancinelli G, Radatti G: Role of carnitine and carnitine palmitoyltransferase as integral components of the pathway for membrane phospholipid fatty acid turnover in intact human erythrocytes. J Biol Chem 267:12673-12681, 1992.
2. Arduini A, Denisova N, Virmani A: Evidence for the involvement of carnitine-dependent long-chain acyltransferases in neuronal triglyceride and phospholipid fatty acid turnover. J Neurochem 62:1530-1538, 1994.
3. Brass E: Carnitine transport. In: L-Carnitine and its Role in Medicine: From Function to Therapy. Edited by Ferrani R, Di Mauro S, Sherwood G. London, Academic Press, pp 21-36, 1992.
4. Brass E: Overview of coenzyme A metabolism and its role in cellular toxicity. Chem. Biol Interact 90:203-214, 1994.
5. Bremer J: Carnitine: Metabolism and function. Physiol Rev 63:1420-1480, 1983.
6. Burgess JR, Stevens L, Zhang W, Peck L:Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr 71: 327S-330S, 2000.
7. Chalmers RA, Roe CR, Tracey BM, Stacey BM, Hopper CL, Millington DS: Secondary carnitine insufficiency in disorders of organic acid metabolism: Modulation of acyl CoA/CoASH rations by L-carnitine in vivo. Biochem Soc Trans 11:724-725, 1983.
8. Colquhoun I, Bounday S:A lack of essential fatty acids as a possible cause of hyperactivity in children. Med Hypotheses 7:673-679, 1981.
9. Conners CK: Conners' Rating Scales - Revised: Technical Manual. New York: MHS, 2001.
10. De Falco FA, D'Angelo E, Grimaldi G, Scafuro F, Sachez F, Caruso G: Effect of chronic treatment with acetyl-L-carnitine in Down Syndrome (Ital). Clin Ter 144:123-127, 1994.
11. Dell'Anna E, Iuvone L, Calzolari S, Geloso MC: Effect of acety-L-carnitine on De Sousa hyperactivity and spatial memory deficits of rats exposed to neonatal anozia. Neurosci Lett 223:201-205, 1997.
12. De Sousa C, Chalmers RA, Stacey TE, Tracey CM, Weaver CM, Bradley D: The response to L-Carnitine and glycine therapy in isovaleric acidemia. Eur J Pediatr 144:451-456, 1986.
13. Dolezal V, Tucek S: Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices. J Neurochem 36:1323-1330, 1998.
14. Goa KL, Brogden RN: L-Carnitine. Drugs 34:1-24, 1987.
15. Gorini A, D'Angelo A, Villa RF: Action of L-acetylcarnitine on different cerebral mitochondrial populations from cerebral cortex. Neurochem Res 23:1485-1491, 1998.
16. Gorini A, D'Angelo A, Villa RF: Energy metabolism of synaptosomal subpopulations from different neuronal systems of rat hippocampus: Effect of L-acetylcarnitine administration in vivo. Neurochem Res 24:617-624, 1999.
17. Guy W: Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology-Revised (U.S. Department of HEW Publication ADM 76-338), Guy W, ed. Rockville, MD: Alcohol, Drug Abuse, and Mental Health Administration, pp 218-222, 1976.
18. Imperato A, Ramacci MT, Angelucci L: Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neurosci Letter 107:251-255, 1989.
19. 11C)acetyl-l-carnitine into the brain: a pet study. Biochem Biophys Res Commun 231:488-493, 1997.
20. Larsson H, Lichtenstein P, Larsson JO: Genetic contributions to the development of ADHD subtypes from childhood to adolescence. J. Am Acad Child Adolesc. Psychiatry 45:973-981, 2006.
21. Maccari F, Arseni A, Chiodi P, Ramacci MT, Angelucci L: Levels of carnitines in brain and other tissues of rats of different ages: Effect of acetylcarnitine administration. Exp Gerontol 25:127-134, 1990.
22. Nicolodi M, Sicuteri F: Acetyl-L-carnitine in behaviour and prophylaxis of migraine in children and preadolescents. Cephalalgia 20:306, 2000. (also presented at Headache World 2000, London, Sept. 3-7, 2000)
23. Rebouche CJ, Seim H: Carnitine metabolism and its regulation in micro-organisms and mammals. Annu Rev Nutr 18:39-61, 1998.
24. Ricciolini R, Scalibastri M, Kelleher JA, Carminati P, Calvani M, Arduini A: Role of acetyl-l-carnitine in rat brain lipogenesis: Implications for polyunsaturated fatty acid biosynthesis. J Neurochem 71:2510-2517, 1998.
25. Roe CR, Millington DS, Maltby DA, Kahler SG, Bohan TP: L-carnitine therapy in isovaleric acidemia. J Clin Invest 74:2290-2295, 1984.
26. Shaffer D, Fisher P, Dulcan M, Davies M, Piacentini J, Schwab-Stone M: The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): Description, acceptability, prevalence rates, and performance in the MECA study. J Am Acad Child Adolesc Psychiatry 35:865-877, 1996.
27. Solanto M, Schulz K, Fan J, Tang C, Newcorn J. Functional MRI in predominantly inattentive and combined subtypes of ADHD [poster]. 12th Scientific Meeting of International Society for Research in Child and Adolescent Psychopathology, Roosevelt Hotel, NYC, 6/22/05-6/25/05, 2005.
28. 13C glucose metabolism in neocortical astrocytes: evidence for mitochondrial heterogeneity. Dev Neurosci 15:351-358, 1993.
29. Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR: Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 62:761-768, 1995.
30. Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein J, Pelham W, Abikoff HB, Newcorn J, Molina B, Hinshaw S, Wells K, Hoza B, Severe JB, Jensen PS, Gibbons R, Hur K, Stehli A, Davies M, March J, Caron M, Volkow ND, & Posner MI, for the MTA Cooperative Group. (in press). Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry, 2007.
31. The MTA Cooperative Group: A 14-Month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086, 1999.
32. The MTA Cooperative Group: The NIMH MTA Follow-up: Changes in effectiveness and growth after the end of treatment. Pediatrics 113:762-769, 2004.
33. Torrioli MG, Vernacotola S, Mariotti P, Bianchi E, Calvani M, De Gaetano A: Double-blind placebo controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet 87:366-368, 1999.
34. Van Oudheusden LJ, Scholte HR: Efficacy of carnitine in the treatment of children with attention deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 67:33-38, 2002.
35. White HL, Scates PW: Acetyl-L-carnitine as a precursor of acetylcholine. Neurochem Res 15:597-601, 1990.